Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients
Department of Emergency Medicine, Columbia University Irving Medical Center, New York, New York
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York
New York State Psychiatric Institute, New York
Health Services Research & Development Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, Seattle, Washington
Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington
Department of Psychiatry, Columbia University Irving Medical Center, New York, New York
San Francisco VA Medical Center, San Francisco, California
Department of General Internal Medicine, University of California, San Francisco
Department of Population Health, Center for Opioid Epidemiology and Policy, New York University Langone Health, New York
Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
Department of Health Systems and Population Health, School of Public Health and Community Medicine, University of Washington, Seattle
VA Manhattan Harbor Healthcare, New York, New York
Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle
Key Points
Question
Were medical cannabis laws (MCLs) or recreational cannabis laws (RCLs) associated with opioid use disorder (OUD) in Veterans Health Administration patients?
Findings
In this cohort study of Veterans Affairs Administration patients, from 2005 to 2022, OUD decreased from 1.12% to 1.06% in states without cannabis laws, increased from 1.13% to 1.19% in states that enacted MCL, and remained stable in states that also enacted RCL. MCL/RCL enactment was associated with greater OUD prevalence, with more substantial increases in OUD among middle-aged and older adults and those with chronic pain.
Meaning
The study results suggest that MCL/RCL enactment was associated with increased OUD, suggesting that cannabis legalization is not an effective intervention to reduce the burden of OUD.
Abstract
Importance
In the context of the US opioid crisis, factors associated with the prevalence of opioid use disorder (OUD) must be identified to aid prevention and treatment. State medical cannabis laws (MCL) and recreational cannabis laws (RCL) are potential factors associated with OUD prevalence.
Objective
To examine changes in OUD prevalence associated with MCL and RCL enactment among veterans treated at the Veterans Health Administration (VHA) and whether associations differed by age or chronic pain.
Design, Setting, and Participants
Using VHA electronic health records from January 2005 to December 2022, adjusted yearly prevalences of OUD were calculated, controlling for sociodemographic characteristics, receipt of prescription opioids, other substance use disorders, and time-varying state covariates. Staggered-adoption difference-in-difference analyses were used for estimates and 95% CIs for the relationship between MCL and RCL enactment and OUD prevalence. The study included VHA patients aged 18 to 75 years. The data were analyzed in December 2023.
Main Outcome and Measures
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) OUD diagnoses.
Results
From 2005 to 2022, most patients were male (86.7.%-95.0%) and non-Hispanic White (70.3%-78.7%); the yearly mean age was 61.9 to 63.6 years (approximately 3.2 to 4.5 million patients per year). During the study period, OUD decreased from 1.12% to 1.06% in states without cannabis laws, increased from 1.13% to 1.19% in states that enacted MCL, and remained stable in states that also enacted RCL. OUD prevalence increased significantly by 0.06% (95% CI, 0.05%-0.06%) following MCL enactment and 0.07% (95% CI, 0.06%-0.08%) after RCL enactment. In patients aged 35 to 64 years and 65 to 75 years, MCL and RCL enactment was associated with increased OUD, with the greatest increase after RCL enactment among older adults (0.12%; 95% CI, 0.11%-0.13%). Patients with chronic pain had even larger increases in OUD following MCL (0.08%; 95% CI, 0.07%-0.09%) and RCL enactment (0.13%; 95% CI, 0.12%-0.15%). Consistent with overall findings, the largest increases in OUD occurred among patients with chronic pain aged 35 to 64 years following the enactment of MCL and RCL (0.09%; 95% CI, 0.07%-0.11%) and adults aged 65 to 75 years following RCL enactment (0.23%; 95% CI, 0.21%-0.25%).
Conclusions and Relevance
The results of this cohort study suggest that MCL and RCL enactment was associated with greater OUD prevalence in VHA patients over time, with the greatest increases among middle-aged and older patients and those with chronic pain. The findings did not support state cannabis legalization as a means of reducing the burden of OUD during the ongoing opioid epidemic.
Teaser
This cohort study examines changes in opioid use disorder prevalence associated with medical and recreational cannabis law enactment among veterans treated at the Veterans Health Administration and whether associations differed by age or chronic pain.
Article notes
Untitled section
Received 2024 Nov 19; Accepted 2025 Feb 7; Collection date 2025 Jun.
Introduction
In the US, opioid use disorder (OUD) affects more than 6.5 million adults.1 OUD, which is characterized by a pattern of opioid use contributing to impairment and distress,2 is associated with opioid overdose3,4,5 and psychiatric, medical, and psychosocial health consequences.1,6,7 Many individual-level factors contribute to OUD risk, including younger age, male sex, opioid use, other substance use disorders (SUDs), and chronic pain persisting 3 months or longer.8,9 Unremitting rates of OUD1 make identifying OUD risk factors an ongoing, urgent public health need to aid in its prevention and treatment.
Cannabis legalization may be 1 factor associated with OUD prevalence. As of 2024, 39 US states have enacted medical cannabis laws (MCLs), and 24 states and Washington, DC, have additionally enacted recreational cannabis laws (RCLs). MCLs/RCLs could be associated with decreased OUD via 2 mechanisms. One involves pain management. While opioid prescriptions have declined,1 they are still widely dispensed for pain.10,11 Chronic pain is now among the most common medical conditions for which cannabis is authorized,12 and many adults perceive cannabis as an effective treatment for chronic pain.13 Ecological studies have indirectly suggested that cannabis is used in place of opioids following MCL enactment,14,15,16,17,18,19,20 potentially reducing opioid-related consequences, including development of OUD. The other mechanism involves cannabis as treatment for OUD, which is now a qualifying condition for medical cannabis in 3 US states (New York, New Jersey, and Pennsylvania).21 In some OUD treatment studies, cannabis use was associated with reductions in opioid dose, less opioid craving, and greater engagement and retention,22,23 potentially reducing OUD burden in states with legal access to cannabis. However, prospective studies have shown that cannabis use is associated with an increased risk of opioid use24,25 and may be used as a complement to opioids,26 which could be associated with increases in OUD if cannabis use is legalized.
Three studies have examined MCL enactment and OUD using data from the National Survey on Drug Use and Health,27,28,29 finding no associations between MCL and OUD. A recent study also found no association between RCL and OUD. However, these studies included adolescents, among whom OUD is rare,30 and used data before enactment of MCL or RCL in many states.
Veterans are disproportionately affected by chronic pain31 and vulnerable to health risks of cannabis use,32 and OUD has increased considerably in the Veterans Health Administration (VHA) since 2005.33 Therefore, using annual electronic health record data from the VHA, which is among the largest integrated health care systems in the US, we investigated trends in OUD from 2005 to 2022, assessing whether MCL/RCL enactment was associated with changes in OUD prevalence. We also examined MCL/RCL–associated changes in OUD by age because OUD rates vary with age34 and prior studies have shown that MCL/RCL are disproportionately associated with the risk of other SUD among older veterans.35,36,37 We further examined associations between MCL/RCL and OUD by chronic pain status, because cannabis legalization may also be associated with increased cannabis use as a substitute for opioids to treat pain, thereby reducing opioid use and the prevalence of OUD.
Methods
Sample and Procedure
Data from January 1, 2005, to December 31, 2022, were obtained from the VHA Corporate Data Warehouse, a database of patients receiving health care at VHA facilities. Data were organized into 18 annual cross-sectional datasets (N = 3 234 382-4 436 913). Veterans aged 18 to 75 years with at least 1 VHA health care encounter during a calendar year were included. We excluded patients in hospice/palliative care or those residing outside the 50 states and Washington, DC. We adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. The institutional review boards at the VAs Puget Sound and New York Harbor Healthcare Systems and New York State Psychiatric Institute approved this study. Waivers/exemptions of informed consent were granted by New York State Psychiatric Institute, VA Puget Sound, and VA New York Harbor Healthcare Systems institutional review boards.
Outcome
Patients with OUD were aggregated yearly from 2005 to 2022. OUD was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (304.0x, 304.7x, and 305.5x) from January 1, 2005, to September 30, 2015, and International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) (F11.1X, F11.2X) from October 1, 2015, to December 31, 2022. Patients were considered positive for OUD if they received 1 or more OUD diagnoses during an outpatient or inpatient encounter at any VA health care facility each year. Codes for OUD in remission were excluded (ICD-9-CM: 304.03X, 304.73, 305.53X; ICD-10-CM: F11.11, F11.21).
Exposure
State-year variables were created to indicate MCL and/or RCL enactment, meaning an operational law in which people had legal cannabis access. Patients’ state of residence was identified by the location of their last VHA health care encounter each year. States were categorized yearly as no MCL/RCL, MCL, and MCL/RCL. From 2005 to 2022, 37 states and Washington, DC, enacted MCL or RCL, including 17 states that enacted only MCL, 12 states and Washington, DC, that enacted MCL and RCL, and 8 states that had MCL before 2005 and enacted RCL during the study period. All states with RCL had previously enacted an MCL.
Covariates
We included covariates associated with OUD.9 Demographic characteristics included sex (female, male), age (<35, 35-64, 65-75 years), and self-reported race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, other race [Asian, American Indian/Alaskan Native, or Pacific Islander/Native Hawaiian] or multiracial, or unknown). We also included time-varying yearly state variables from the American Community Survey data, including state percentages of male individuals, self-reported race and ethnicity (Hispanic, non-Hispanic Black, or non-Hispanic White), age 18 years or older, unemployment, an income less than the federal poverty level, and median household income using R tidycensus (R Foundation). We used 1-year percentages for years 2005 to 2008 and 5-year percentages from 2009 to 2022.38 Consistent with previous articles,35,36 we included ICD-9-CM or ICD-10-CM codes to assess chronic pain conditions (yes, no). We also included ICD codes for other substance use disorders (yes, no; eAppendix in Supplement 1). We required 2 or more outpatient or 1 or more inpatient pain diagnoses and 1 outpatient or inpatient diagnosis within each study year for pain and SUD, respectively. Measures of 30-day or longer receipt of prescription opioids (yes, no) and state enactment of a prescription drug monitoring program (PDMP) mandatory access law (requiring that clinicians review the PDMP before prescribing opioids)39,40 were also examined.
Statistical Analysis
OUD prevalences were aggregated annually, overall, and as a function of cannabis legalization status (MCL, RCL, or no cannabis law). We calculated yearly adjusted OUD prevalence using linear binomial regression models, including year and an interaction term for MCL/RCL status year, which were adjusted for sex, race and ethnicity, continuous age, SUD, receipt of prescription opioids, PDMP mandatory access law, and state-level covariates. We then reran models stratified by age groups (<35, 35-64, or 65-75 years)41,42 and chronic pain status (eMethods in Supplement 1).35,36
The associations between cannabis legalization and OUD were assessed using staggered-adoption difference-in-difference (DiD) estimates, overall and stratified by age groups controlling for fixed state and time effects. The DiD model used MCL/RCL–enacted states as independent controls, comparing years after MCL/RCL enactment with years before enactment, accounting for OUD trends from no MCL/RCL states during the same period. For each state-year, a time-varying measure was created to indicate MCL/RCL status. DiD effects were estimated as the change in OUD associated with state transition from no cannabis laws to MCL and from MCL to MCL/RCL, using comparator data from the 13 no cannabis law states and the 17 MCL states that did not enact RCL by 2022. DiD estimates and 95% CIs were derived by fitting a linear binomial regression model at the individual level that included state fixed effects, year, time-varying MCL/RCL status, individual demographic characteristics (including SUD), receipt of prescription opioids, PDMP mandatory access laws, and state-level covariates. The resulting DiD estimates indicated the association with OUD prevalence of a state moving from no MCL/RCL to MCL or from MCL to RCL. Preenactment OUD trends were examined and found to be consistent with the parallel trends assumption of DiD analyses (eMethods in Supplement 1).
We also conducted 2 sets of sensitivity analyses using an approach similar to main analyses. We examined the association between legalized dispensaries and OUD by replacing our MCL/RCL variables with state-year variables indicating years that legally protected dispensaries were operational for medical cannabis in MCL states and for recreational cannabis also enacting RCL,43 as well as the lagged effects of cannabis legalization by replacing MCL/RCL state/year variables with 1-year postenactment dates, overall and by chronic pain status.
Results
Sample Characteristics
From 2005 to 2022, most patients were male (86.7.%-95.0%) and non-Hispanic White (70.3%-78.7%); the yearly mean age was 61.9 to 63.6 years. The prevalence of younger veterans (aged <35 years), women, and patients of racial and ethnic minority groups increased during the study period (eTable 3 in Supplement 1).
Overall and Age-Stratified OUD Prevalence by MCL/RCL Status
The adjusted overall prevalence of OUD remained stable from 1.12% in 2005 to 1.12% in 2022, peaking at 1.25% in 2017 (eTable 4 in Supplement 1). From 2005 to 2022, OUD prevalence decreased by 0.06% in no cannabis law states, increased by 0.06% in MCL states, and remained stable in states with additional RCLs (Figure 1; Table 1). Yearly age-stratified prevalences of OUD by MCL/RCL status are shown in eTable 5 in Supplement 1. From 2005 to 2022, in no cannabis law states, OUD increased by 0.07% in patients aged 35 to 64 years and 0.16% in those aged 65 to 75 years and declined by 0.07% in patients younger than 35 years. In MCL and RCL states, OUD increased in patients aged 65 to 75 years (MCL, 0.27%; RCL, 0.41%) but decreased in patients younger than 35 years (MCL, −0.25%; RCL, −0.21%) and aged 35 to 64 years (MCL, −0.02%; RCL, −0.46%).
| Type of state | Overall | Age 18-34 y | Age 35-64 y | Age 65-75 y | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OUD prevalencea | Absolute change, % | OUD prevalenceb | Absolute change, % | OUD prevalenceb | Absolute change, % | OUD prevalenceb | Absolute change, % | |||||
| 2005 | 2022 | 2005 | 2022 | 2005 | 2022 | 2005 | 2019 | |||||
| No. of patients | 3 234 382 | 4 436 883 | NA | 182 809 | 468 729 | NA | 1 993 492 | 2 338 600 | NA | 1 058 081 | 1 629 554 | NA |
| No CLc | 1.12 | 1.06 | −0.06 | 1.54 | 1.47 | −0.07 | 0.49 | 0.56 | 0.08 | 0.45 | 0.61 | 0.16 |
| MCLd | 1.13 | 1.19 | 0.06 | 1.71 | 1.46 | −0.25 | 0.73 | 0.71 | −0.02 | 0.45 | 0.72 | 0.27 |
Overall and Age-Stratified Associations of MCL/RCL Enactment and OUD Prevalence
In the overall sample, DiD results indicated a 0.06% (95% CI, 0.05%-0.06%; P < .001) increase in OUD prevalence following MCL enactment and a 0.07% (95% CI, 0.06-0.08; P < .001) increase after RCL enactment. In patients aged 35 to 64 years, MCL enactment was associated with a 0.05% (95% CI, 0.04%-0.06%; P < .001) increase in OUD prevalence and 0.04% (95% CI, 0.02%-0.05%; P < .001) increase in OUD after RCL enactment. These results were consistent in the group aged 65 to 75 years, for whom MCL and RCL enactment were associated with a 0.04% (95% CI, 0.03%-0.04%; P < .001) and 0.12% (95% CI, 0.11%-0.13%; P < .001) increase in OUD, respectively. Cannabis law enactment was not associated with OUD in the group aged 18 to 34 years (Table 2).
| Change in state lawa | Overall | Age 18-34 y | Age 35-64 y | Age 65-75 y | ||||
|---|---|---|---|---|---|---|---|---|
| DiD law result (95% CI)b | P value | DiD law result (95% CI)c | P value | DiD law result (95% CI)c | P value | DiD law result (95% CI)c | P value | |
| No CL to MCL | 0.06 (0.05 to 0.06) | <.001 | 0.014 (−0.004 to 0.032) | .12 | 0.050 (0.041 to 0.060) | <.001 | 0.036 (0.029 to 0.042) | <.001 |
| MCL to RCL | 0.07 (0.06 to 0.08) | <.001 | −0.018 (−0.039 to 0.003) | .10 | 0.035 (0.022 to 0.048) | <.001 | 0.119 (0.108 to 0.130) | <.001 |
State-Specific Associations of MCL/RCL Enactment and OUD
Of the 17 states that only enacted MCL, 9 states demonstrated a significant increase in OUD, 1 state had a significant decline in OUD (Arizona), and 7 states showed no significant change in OUD. In the 20 states that also passed RCL, enactment was associated with increased OUD prevalence in 17 states. Washington, DC, was the only jurisdiction where RCL enactment was associated with a decline in OUD (Figure 2).
Compared with patients without chronic pain (approximately 1.2-2.5 million patients per year), those with chronic pain (approximately 1.9-2.0 million patients per year) were disproportionately affected by OUD following MCL/RCL enactment (eTable 6 in Supplement 1). Among patients with chronic pain, MCL and RCL enactment were associated with a 0.08% (95% CI, 0.07%-0.09%; P < .001) and 0.13% (95% CI, 0.12%-0.15%; P < .001) increase in OUD prevalence, respectively, while patients without chronic pain had only a 0.03% (95% CI, 0.02%-0.03%; P < .001) and a 0.01% (95% CI, 0.01%-0.02%; P = .03) increase in OUD following MCL and RCL enactment, respectively. In patients aged 35 to 64 years with chronic pain, MCL enactment and RCL enactment was associated with a 0.09% (95% CI, 0.07%-0.11%; P < .001) increase in OUD (eTable 7 in Supplement 1). Cannabis legalization was also associated with increased OUD in patients aged 65 to 75 years with chronic pain, an increase of 0.06% (95% CI, 0.04%-0.07%; P < .001) in MCL states and 0.23% (95% CI, 0.21%-0.25%; P < .001) in RCL states. OUD also increased in patients aged 65 to 75 years without chronic pain, but to a lesser degree, with an increase of 0.02% (95% CI, 0.01%-0.02%; P < .001) after MCL enactment and 0.03% (95% CI, 0.02%-0.04%; P < .001) following RCL enactment. In patients aged 18 to 34 years with chronic pain, MCL enactment was associated with a 0.07% increase in OUD (95% CI, 0.04%-0.10%; P < .001), with no significant change in OUD following RCL enactment.
Sensitivity Analyses
Findings from sensitivity analyses were generally consistent with the main results (eTables 8-10 in Supplement 1). Enactment of operational medical dispensaries was associated with 0.07% (95% CI, 0.06%-0.08%; P < .001) increase in OUD compared with states without medical dispensaries, while operational recreational dispensaries further increased OUD by 0.05% (95% CI, 0.04%-0.06%; P < .001) compared with states with only medical dispensaries (eTable 8 in Supplement 1). Following the operationalization of medical cannabis dispensaries, OUD increases were greatest in the group aged 35 to 64 years, particularly those with chronic pain (DiD, 0.12%; 95% CI, 0.10%-0.13%; P < .001), while patients aged 65 to 75 years with chronic pain (DiD, 0.20%; 95% CI, 0.17%-0.22%; P < .001) were most affected by the operationalization of recreational dispensaries (eTable 9 in Supplement 1). Using 1-year postenactment lags did not significantly change the results (eTables 10 and 11 in Supplement 1).
Discussion
In this cohort study, we examined changes in the yearly prevalence of OUD that was associated with MCL and/or RCL enactment among VHA patients from 2005 to 2022. MCL enactment was associated with small, yet significant increases in OUD overall and in middle-aged and older-aged adults. RCL enactment was associated with further increases in OUD, particularly among older adults with chronic pain. These results were similar in sensitivity analyses examining operational cannabis dispensaries and 1-year lags. Our findings did not support MCL or RCL enactment as a means of reducing the burden of OUD. Instead, MCLs/RCLs could potentially be associated with an increased OUD risk among VHA patients during the ongoing opioid epidemic. These are timely considerations given that the US government has considered cannabis policy reform for the VHA.44,45
There are several possible explanations of our findings. Cannabis use may be associated with an increased risk of consuming other substances, either by providing more opportunities through access to the same illicit markets or peers who use drugs, or by lowering the threshold for addiction to other substances, including opioids.46 Clinical and epidemiological studies have also shown increasingly prevalent patterns of course, in which individuals who use cannabis are more likely to use opioids.26,47 This course may stem from shared risk factors or the use of cannabis to enhance the effects of opioids. Several prospective studies have demonstrated that cannabis use is associated with an increased risk of opioid use and may be used with opioids, for instance, to augment relief of pain,25,26,48,49 a condition which was prevalent in our sample. A 25-year longitudinal study found a strong prospective association between use of cannabis and subsequent use of opioids, with the likelihood increasing as cannabis use frequency increased.48 Similar findings were observed in another prospective study of adults, in which nonmedical opioid use was more likely to occur in those with vs without cannabis use, with increasing risk among those with pain.24 OUD is more likely to develop in individuals using cannabis, particularly among those with frequent cannabis use,24 which has become substantially more prevalent in the US in recent years.50 Our study suggests that as access to cannabis increases with MCL/RCL, individuals may be more likely to experience these risks.
Our findings were consistent with 3 national studies that showed that MCL was not associated with a reduced prevalence of OUD,27,28,29 with adults 50 years or older demonstrating the greatest increase in OUD following MCL enactment.28 Some ecological studies have suggested that cannabis legalization is associated with reductions in opioid use,14 a necessary although not sufficient condition for the development of OUD. However, a study of national clinical data found no MCL-related reductions in opioid use among patients with chronic pain.51 In our study, VHA patients with chronic pain (>50% of patients)36 demonstrated increased OUD following MCL enactment. While medical cannabis has been authorized for chronic pain, evidence for its efficacy as a pain treatment remains inconclusive.52 Therefore, adults unable to manage their chronic pain with cannabis may transition to use of prescribed or nonprescribed opioids or augment the effects of opioids with cannabis,26 putting them at risk for OUD. Older adults are particularly vulnerable to the adverse effects of cannabis due to their lower substance use tolerance,53,54 increasing their risk of developing OUD if cannabis serves as a gateway to opioid use. This could be especially salient among older VHA patients, who may not have used cannabis during their earlier adult years when federal and military policy prohibited use, but whose willingness to use cannabis may have increased with exposure to marketing for cannabis as a medical treatment.55,56
RCL enactment was also associated with increases in OUD prevalence overall and in most individual states. These findings contrast with a recent study that showed that RCL enactment was not associated with OUD29 in a sample that was predominantly younger than 35 years. However, the age distribution of our sample was markedly different and comprised of mostly middle-aged and older adults. When we stratified by age group, RCL was not associated with OUD in younger patients (age 18-34 years) with or without chronic pain, as cannabis use was already prevalent in this age group before enactment of cannabis laws, and the incremental effects of RCL in this group may have been minimal.34 However, RCL enactment was associated increased OUD in middle-aged (age 35-64 years) and older adults (age 65-75 years), particularly in older adults. Older patients may have been naive to the highly potent forms of cannabis that became available after RCL enactment,55 and increased recreational cannabis use following RCL may have served as a risk factor to opioid use and OUD, especially in older adults with chronic pain. Future research is needed to understand if these associations extend to these age groups in the general population, which will have implications for tailored OUD prevention strategies.
Limitations
This study had limitations. VHA veterans are mostly male, White, and older, with lower financial resources and high rates of medical comorbidities.57 Therefore, findings may not be generalizable, although they also suggest that MCL/RCL enactment disproportionately affects OUD in older patients and those with chronic pain, 2 groups that are increasing in the general population.58 Second, medical conditions designated with ICD codes may be underdiagnosed, and OUD may be underestimated or misdiagnosed in health record or claims data, including in the VHA.59,60,61 However, we limited OUD misclassification by excluding OUD cases in remission, and OUD rates in our sample were similar to National Survey on Drug Use and Health rates, a nationally representative data source.62 Third, the ICD-9-CM to ICD-10-CM transition may have affected clinical estimates of OUD. However, our prevalences of OUD resembled those observed in the general population and were consistent with non-VHA data demonstrating that OUD peaked around 2016 to 2017.1 Our DiD estimates accounted for the transition from ICD-9 to ICD-10 by using states with no MCL/RCL as contemporaneous secular controls. Therefore, this increase in OUD likely did not meaningfully affect our results. Fourth, the VHA health record lacks information on cannabis use, so we were unable to assess frequency of use, route of administration, or cannabis potency in associated with OUD. Fifth, we did not collect data on patient disability or changes to VHA health care eligibility due to cannabis legalization. These are important areas for future research, especially given increasing cannabis potency and the risk of psychiatric and SUDs and potential disability due to these health conditons.63
Conclusions
This cohort study demonstrated that MCL was associated with increased rates of OUD, with even greater increases in middle-aged and older adults, and patients with chronic pain who were residing in states that also enacted RCL. Findings suggest that cannabis policies and increasing access to legal cannabis were not associated with a reduced burden of OUD. US states considering cannabis legislation to combat the opioid epidemic should consider potential unintended consequences on the prevalence of OUD and other opioid-related health outcomes.64 Our results should encourage careful regulation of cannabis distribution following legalization and monitoring of OUD symptoms among patients residing in MCL/RCL states, alongside concerted surveillance efforts in older adults who may be particularly susceptible to cannabis and opioid use risks. Because our study was among the first to our knowledge to examine associations of MCL/RCL with OUD, general population studies are needed to assess the effect of these laws on OUD and other opioid-related harms, including opioid overdose. Moreover, future studies should examine whether certain clinical populations are susceptible to OUD following MCL/RCL enactment, including patients with psychiatric disorders or those with specific pain conditions, or whether cannabis laws may reduce substance use–related stigma or increase substance use reporting and treatment utilization and whether these factors could partially account for changes in OUD following enactment of MCL/RCL. These studies will help identify the mechanisms of the associations we found, inform clinical policies associated with cannabis use, and guide future treatment and prevention efforts of OUD during a time when rates of OUD and opioid overdoses remain high.1,5
Untitled section
References
Untitled section
References
- 1.Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052. doi: 10.1016/j.dadr.2022.100052
- 2.American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
- 3.Bahji A, Cheng B, Gray S, Stuart H. Mortality among people with opioid use disorder: a systematic review and meta-analysis. J Addict Med. 2020;14(4):e118-e132. doi: 10.1097/ADM.0000000000000606
- 4.Bohnert ASB, Ilgen MA. Understanding links among opioid use, overdose, and suicide. N Engl J Med. 2019;380(1):71-79. doi: 10.1056/NEJMra1802148
- 5.US Centers for Disease Control and Prevention . US opioid dispensing rate maps. https://www.cdc.gov/overdose-prevention/data-research/facts-stats/us-dispensing-rate-maps.html
- 6.Yamamoto A, Needleman J, Gelberg L, Kominski G, Shoptaw S, Tsugawa Y. Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. Soc Sci Med. 2019;242:112585. doi: 10.1016/j.socscimed.2019.112585
- 7.Santo T Jr, Campbell G, Gisev N, et al. Prevalence of mental disorders among people with opioid use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2022;238:109551. doi: 10.1016/j.drugalcdep.2022.109551
- 8.Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328-e332. doi: 10.1097/j.pain.0000000000002291
- 9.Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748. doi: 10.1213/ANE.0000000000002496
- 10.Olfson M, Wang S, Wall MM, Blanco C. Trends in opioid prescribing and self-reported pain among US adults. Health Aff (Millwood). 2020;39(1):146-154. doi: 10.1377/hlthaff.2019.00783
- 11.Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription opioid use among adults with chronic pain: United States, 2019. Natl Health Stat Report. 2021;(162):1-9.
- 12.Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med. 2020;35(7):1979-1986. doi: 10.1007/s11606-020-05800-7
- 13.Keyhani S, Steigerwald S, Ishida J, et al. Risks and benefits of marijuana use: a national survey of U.S. adults. Ann Intern Med. 2018;169(5):282-290. doi: 10.7326/M18-0810
- 14.Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med. 2018;178(5):667-672. doi: 10.1001/jamainternmed.2018.0266
- 15.McMichael BJ, Van Horn RL, Viscusi WK. The impact of cannabis access laws on opioid prescribing. J Health Econ. 2020;69:102273. doi: 10.1016/j.jhealeco.2019.102273
- 16.Shah A, Hayes CJ, Lakkad M, Martin BC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med. 2019;34(8):1419-1426. doi: 10.1007/s11606-018-4782-2
- 17.Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med. 2018;178(5):673-679. doi: 10.1001/jamainternmed.2018.1007
- 18.Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144-150. doi: 10.1016/j.drugalcdep.2017.01.006
- 19.Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29-42. doi: 10.1016/j.jhealeco.2017.12.007
- 20.Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. Changes in prescribed opioid dosages among patients receiving medical cannabis for chronic pain, New York State, 2017-2019. JAMA Netw Open. 2023;6(1):e2254573. doi: 10.1001/jamanetworkopen.2022.54573
- 21.Shover CL, Vest NA, Chen D, et al. Association of state policies allowing medical cannabis for opioid use disorder with dispensary marketing for this indication. JAMA Netw Open. 2020;3(7):e2010001. doi: 10.1001/jamanetworkopen.2020.10001
- 22.Lake S, St Pierre M. The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: a systematic review. Clin Psychol Rev. 2020;82:101939. doi: 10.1016/j.cpr.2020.101939
- 23.Wiese B, Wilson-Poe AR. Emerging evidence for cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179-189. doi: 10.1089/can.2018.0022
- 24.Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry. 2018;175(1):47-53. doi: 10.1176/appi.ajp.2017.17040413
- 25.Wilson J, Mills K, Freeman TP, Sunderland M, Visontay R, Marel C. Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction. 2022;117(2):284-298. doi: 10.1111/add.15581
- 26.Gorfinkel LR, Stohl M, Greenstein E, Aharonovich E, Olfson M, Hasin D. Is cannabis being used as a substitute for non-medical opioids by adults with problem substance use in the United States? a within-person analysis. Addiction. 2021;116(5):1113-1121. doi: 10.1111/add.15228
- 27.Ali MM, McClellan C, West KD, Mutter R. Medical marijuana laws, marijuana use, and opioid-related outcomes among women in the United States. Womens Health Issues. 2021;31(1):24-30. doi: 10.1016/j.whi.2020.09.003
- 28.Segura LE, Mauro CM, Levy NS, et al. Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Netw Open. 2019;2(7):e197216-e197216. doi: 10.1001/jamanetworkopen.2019.7216
- 29.Martins SS, Bruzelius E, Mauro CM, et al. The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: does it depend on prior history of cannabis use? Int J Drug Policy. 2025;136:104687. doi: 10.1016/j.drugpo.2024.104687
- 30.Lynch V, Clemans-Cope L, Winiski E. Prevalence of opioid use disorder and other substance use among adolescents and young adults in Medicaid/CHIP, 2015-2019. Journal of Child & Adolescent Substance Abuse. 2020;29(4-6):232-245. doi: 10.1080/1067828X.2021.2015733
- 31.Mannes ZL, Stohl M, Fink DS, et al. Non-pharmacological treatment for chronic pain in US veterans treated within the Veterans Health Administration: implications for expansion in US healthcare systems. J Gen Intern Med. 2022;37(15):3937-3946. doi: 10.1007/s11606-021-07370-8
- 32.Livne O, Mannes ZL, McDowell YE, et al. Mental and physical health conditions among U.S. veterans with cannabis use and cannabis use disorders. Curr Addict Rep. 2023;10(3):441-457. doi: 10.1007/s40429-023-00490-7
- 33.Gorfinkel LR, Malte CA, Fink DS, et al. Trends in opioid use disorder in the Veterans Health Administration, 2005-2022. JAMA Netw Open. 2024;7(12):e2451821. doi: 10.1001/jamanetworkopen.2024.51821
- 34.Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Accessed March 20, 2024. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
- 35.Hasin DS, Wall MM, Alschuler DM, et al. Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration system, 2005 to 2019: a repeated, cross-sectional study. Lancet Psychiatry. 2023;10(11):877-886. doi: 10.1016/S2215-0366(23)00268-7
- 36.Mannes ZL, Malte CA, Olfson M, et al. Increasing risk of cannabis use disorder among U.S. veterans with chronic pain: 2005-2019. Pain. 2023;164(9):2093-2103. doi: 10.1097/j.pain.0000000000002920
- 37.Hasin DS, Wall MM, Choi CJ, et al. State cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2005 to 2019. JAMA Psychiatry. 2023;80(4):380-388. doi: 10.1001/jamapsychiatry.2023.0019
- 38.Walker K, Herman M. tidycensus: load US Census boundary and attribute data as ‘tidyverse’ and ‘sf’-ready data frames. Accessed March 20, 2024. https://walker-data.com/tidycensus/
- 39.Nguyen HV, McGinty EE, Mital S, Alexander GC. Recreational and medical cannabis legalization and opioid prescriptions and mortality. JAMA Health Forum. 2024;5(1):e234897. doi: 10.1001/jamahealthforum.2023.4897
- 40.Puac-Polanco V, Chihuri S, Fink DS, Cerdá M, Keyes KM, Li G. Prescription drug monitoring programs and prescription opioid–related outcomes in the United States. Epidemiol Rev. 2020;42(1):134-153. doi: 10.1093/epirev/mxaa002
- 41.Hasin DS, Saxon AJ, Malte C, et al. Trends in cannabis use disorder diagnoses in the U.S. Veterans Health Administration, 2005-2019. Am J Psychiatry. 2022;179(10):748-757. doi: 10.1176/appi.ajp.22010034
- 42.Livne O, Malte CA, Olfson M, et al. Trends in prevalence of cannabis use disorder among U.S. veterans with and without psychiatric disorders between 2005 and 2019. Am J Psychiatry. 2024;181(2):144-152. doi: 10.1101/2023.05.24.23290358
- 43.RAND Corporation . OPTIC-vetted policy data sets. Accessed January 3, 2025. https://www.rand.org/health-care/centers/optic/resources/datasets.html
- 44.US Department of Veterans Affairs . Access to VHA clinical programs for veterans participating in state-approved marijuana programs. Accessed March 30, 2024. https://www.publichealth.va.gov/marijuana.asp.
- 45.US Congress . VA Medicinal Cannabis Research Act of. 2023. Accessed March 30, 2024. https://www.congress.gov/118/bills/s1204/BILLS-118s1204is.pdf
- 46.Kandel D, Kandel E. The fateway hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatr. 2015;104(2):130-137. doi: 10.1111/apa.12851
- 47.Liang D, Wallace MS, Shi Y. Medical and non-medical cannabis use and risk of prescription opioid use disorder: Findings from propensity score matching. Drug Alcohol Rev. 2019;38(6):597-605. doi: 10.1111/dar.12964
- 48.Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101(4):556-569. doi: 10.1111/j.1360-0443.2005.01322.x
- 49.Caputi TL, Humphreys K. Medical marijuana users are more likely to use prescription drugs medically and nonmedically. J Addict Med. 2018;12(4):295-299. doi: 10.1097/ADM.0000000000000405
- 50.Caulkins JP. Changes in self-reported cannabis use in the United States from 1979 to 2022. Addiction. 2024;119(9):1648-1652. doi: 10.1111/add.16519
- 51.McGinty EE, Tormohlen KN, Seewald NJ, et al. Effects of U.S. state medical cannabis laws on treatment of chronic noncancer pain. Ann Intern Med. 2023;176(7):904-912. doi: 10.7326/M23-0053
- 52.Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932-1954. doi: 10.1097/j.pain.0000000000001293
- 53.Kansagara D, Becker WC, Ayers C, Tetrault JM. Priming primary care providers to engage in evidence-based discussions about cannabis with patients. Addict Sci Clin Pract. 2019;14(1):42. doi: 10.1186/s13722-019-0171-3
- 54.Kuerbis A, Sacco P, Blazer DG, Moore AA. Substance abuse among older adults. Clin Geriatr Med. 2014;30(3):629-654. doi: 10.1016/j.cger.2014.04.008
- 55.Lewis N, Sznitman SR. Engagement with medical cannabis information from online and mass media sources: is it related to medical cannabis attitudes and support for legalization? Int J Drug Policy. 2019;73:219-227. doi: 10.1016/j.drugpo.2019.01.005
- 56.Kaufmann CN, Kim A, Miyoshi M, Han BH. Patterns of medical cannabis use among older adults from a cannabis dispensary in New York State. Cannabis Cannabinoid Res. 2022;7(2):224-230. doi: 10.1089/can.2020.0064
- 57.Fink DS, Stohl M, Mannes ZL, et al. Comparing mental and physical health of U.S. veterans by VA healthcare use: implications for generalizability of research in the VA electronic health records. BMC Health Serv Res. 2022;22(1):1500. doi: 10.1186/s12913-022-08899-y
- 58.Zajacova A, Grol-Prokopczyk H, Zimmer Z. Pain trends among American adults, 2002-2018: patterns, disparities, and correlates. Demography. 2021;58(2):711-738. doi: 10.1215/00703370-8977691
- 59.US Department of Veterans Affairs . Veterans Health Administration: review of clinical care transition from the Department of Defense to the Veterans Health Administration for service members with opioid use disorder. Accessed March 30, 2024. https://www.vaoig.gov/sites/default/files/reports/2023-06/VAOIG-21-02110-138.pdf
- 60.Scherrer JF, Sullivan MD, LaRochelle MR, Grucza R. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addict Sci Clin Pract. 2023;18(1):49. doi: 10.1186/s13722-023-00405-x
- 61.Howell BA, Abel EA, Park D, Edmond SN, Leisch LJ, Becker WC. Validity of incident opioid use disorder (OUD) diagnoses in administrative data: a chart verification study. J Gen Intern Med. 2021;36(5):1264-1270. doi: 10.1007/s11606-020-06339-3
- 62.Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488
- 63.Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9(9):736-750. doi: 10.1016/S2215-0366(22)00161-4
- 64.Tormohlen KN, Bicket MC, White S, et al. The state of the evidence on the association between state cannabis laws and opioid-related outcomes: a review. Curr Addict Rep. 2021;8(4):538-545. doi: 10.1007/s40429-021-00397-1